A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Head and Neck Cancer|Non Small Cell Lung Cancer|Gastrointestinal Cancer|Triple Negative Breast Cancer|Ovarian Carcinoma
Interventions: DRUG: TJ004309
Sponsor: I-Mab Biopharma US Limited